The results indicated that knocking down MBD2 increased the sensitivity of TFK1 and RBE to cisplatin, resulting in lower IC50 values (Fig. 2G, Figure S1A-B), whereas the opposite outcomes were observed in CCA cells overexpressing MBD2 (Fig. 2N, Figure S1C-D). The gene discussed is MBD2; the disease is cholangiocarcinoma.